Andrew Tsai
Stock Analyst at Jefferies
(3.26)
# 1,055
Out of 5,182 analysts
29
Total ratings
60%
Success rate
13.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Buy | $145 | $88.68 | +63.51% | 1 | Apr 13, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $182.72 | +34.08% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $23.26 | +28.98% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.57 | +57.48% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $52.85 | -43.24% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $329.60 | +36.53% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $29.11 | +9.93% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $25.71 | -2.76% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $187.88 | +1.13% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $20.42 | +71.40% | 3 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $34.93 | -14.11% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $71.67 | -2.33% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.68 | -32.07% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $15.80 | +70.89% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $7.25 | +79.31% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $36.36 | -3.74% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.68 | +78.57% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.77 | +466.04% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $55.41 | -58.49% | 1 | Jun 1, 2020 |
Bright Minds Biosciences
Apr 13, 2026
Initiates: Buy
Price Target: $145
Current: $88.68
Upside: +63.51%
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $182.72
Upside: +34.08%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $23.26
Upside: +28.98%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.57
Upside: +57.48%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $52.85
Upside: -43.24%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $329.60
Upside: +36.53%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $29.11
Upside: +9.93%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $25.71
Upside: -2.76%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $187.88
Upside: +1.13%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $20.42
Upside: +71.40%
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $34.93
Upside: -14.11%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $71.67
Upside: -2.33%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.68
Upside: -32.07%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $15.80
Upside: +70.89%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $7.25
Upside: +79.31%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $36.36
Upside: -3.74%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.68
Upside: +78.57%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.77
Upside: +466.04%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $55.41
Upside: -58.49%